Ushiku, Japan

Masahiko Morita


Average Co-Inventor Count = 7.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Ushiku, JP (2005 - 2006)
  • Osaka, JP (2008)

Company Filing History:


Years Active: 2005-2008

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Masahiko Morita: Innovator in Pharmaceutical Research

Introduction

Masahiko Morita is a notable inventor based in Ushiku, Japan. He has made significant contributions to the field of pharmaceutical research, particularly in the development of methods for evaluating phosphatase inhibitors and understanding amyloid-β protein aggregation.

Latest Patents

Morita holds 3 patents, with his latest inventions focusing on critical areas of medical research. One of his patents details methods of evaluating phosphatase inhibitors, identifying specific clones that suppress CREB activation. This invention provides evaluation methods using these genes and proteins, which have implications for treating memory disorders and neurodegenerative diseases. Another significant patent addresses amyloid-β protein aggregation-regulating factors, offering insights into therapeutic agents for Alzheimer's disease by regulating protein activity related to amyloid-β aggregation.

Career Highlights

Throughout his career, Morita has worked with prominent companies in the pharmaceutical industry, including Fujisawa Pharmaceutical Company, Ltd. and Astellas Pharma GmbH. His work has been instrumental in advancing research and development in the field of neuropharmacology.

Collaborations

Morita has collaborated with several professionals in his field, including Mayako Yamazaki and Susumu Satoh. These collaborations have contributed to the success of his research and the development of innovative solutions in pharmaceutical science.

Conclusion

Masahiko Morita's contributions to pharmaceutical research and his innovative patents highlight his role as a key figure in the industry. His work continues to influence the development of therapeutic agents for critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…